Chris Hughes reveals he's in hospital with alcohol hepatitis after 'torturing' his body
The Love Island star, 30, took to Instagram on Wednesday to reveal he had alcohol hepatitis after heading on a boozy night out on Saturday night. (Source: the Mail online | Health)
Source: the Mail online | Health - February 1, 2023 Category: Consumer Health News Source Type: news

David J. Miller and Minnesota Independent Cooperative, Inc., Convicted in Multi-Million-Dollar Prescription Drug Diversion Scheme
FDA OCI, Devid Jess Miller, Santa Ana, CA, Minnesota Independent Cooperative, MIC, unlicensed, fraudulent, distribution, Rx, prescription, drugs, racketeering, enterprise, diverted, tampered, HIV, hepatitis C, mental disorders, supply chain, Mihran Stepanyan, Artur Stepanyan, laundering, criminal, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - January 27, 2023 Category: Medical Law Authors: DOJ Source Type: news

FDA Moves to Ease Rules for Blood Donations from Gay Men
WASHINGTON — The U.S. is moving to further ease restrictions on blood donations from gay and bisexual men and other groups that typically face higher risks of HIV. The Food and Drug Administration on Friday announced draft guidelines that would do away with the current three-month abstinence requirement for donations from men who have sex with men. Instead, all potential donors would be screened with a new questionnaire that evaluates their individual risks for HIV based on sexual behavior, recent partners, and other factors. If finalized, many gay and bisexual men in monogamous relationships would be able to donate ...
Source: TIME: Health - January 27, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized healthscienceclimate Public Health wire Source Type: news

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Hepatitis C Virus-specific Immune Responses Following DAAs Hepatitis C Virus-specific Immune Responses Following DAAs
This study investigated whether treatment of acute HCV infection with direct-acting antivirals prevents establishment of, or reverses, T-cell exhaustion.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 26, 2023 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Rapid tests make diagnosis of Hepatitis C more accessible and closer to the community, study finds
A new study has shown the benefit of using a quick clinic-based diagnostic test for hepatitis C virus (HCV) infection over a standard laboratory-based test. The findings from the study has led to World Health Organization (WHO) guidelines recommending the adoption of the point-of-care (POC) HCV test. (Source: University of Bristol news)
Source: University of Bristol news - January 25, 2023 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences, Institutes, Institutes, Bristol Population Health Science Institute; Press Release Source Type: news

WHO art competition for school students & quot;75 years of improving public health & quot;
Dear students, On 7 April 2023  ̶  World Health Day  ̶  the World Health Organization will observe its 75th birthday. In 1948, countries of the world came together and founded WHO to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere could attain the highest level of health and well-being. To advance the health and security of all people, WHO works with governments, communities, international organizations, foundations, advocates, researchers and health workers, and WHO’s 75th anniversary year is an opportunity to look back at the public health succe...
Source: WHO EMRO News - January 25, 2023 Category: Middle East Health Source Type: news

Fewer Medi-Cal patients got crucial treatment for hepatitis C amid pandemic
Hepatitis C can be cured in most cases with a few months of medication. The number of Medi-Cal patients getting the treatment dropped during the pandemic. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - January 22, 2023 Category: Science Authors: Emily Alpert Reyes Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news

QuickStats: Percentage of Adults Aged ≥18 Years Who Have Ever Had Hepatitis, by Age Group and Sex - National Health Interview Survey, United States, 2021
This report describes 2021 data from National Center for Health Interview Survey on the percentage of adults who have ever had hepatitis by age group and sex. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - January 12, 2023 Category: American Health Tags: Adult Health Hepatitis MMWR Morbidity & Mortality Weekly Report Source Type: news

Falling Treatment Uptake in the Hepatitis C Care Cascade Falling Treatment Uptake in the Hepatitis C Care Cascade
What are the main factors which are hindering high-income countries from achieving the World Health Organization hepatitis C elimination targets?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 12, 2023 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Strong Support to Provide DAA Therapy to All Patients With HCV Strong Support to Provide DAA Therapy to All Patients With HCV
Direct-acting antiviral therapy significantly improves liver outcomes, nonliver outcomes, and long-term survival for patients with chronic hepatitis C virus, regardless of disease stage.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 11, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news

Sex Differences in HBV-Associated Liver Cancer Sex Differences in HBV-Associated Liver Cancer
Liver cancer genetics and biology differ between men and women and help explain why aflatoxin exposure increases the risk in hepatitis B virus (HBV) –infected patients, particularly in men.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study finds hepatitis C cure saved Medicaid $15 billion
New research published in theAmerican Journal of Managed Care (AJMC) underscores the critical role that medicines play in improving health and reducing disease complications and other, often costly, medical care and services. The study finds that since curative direct-acting antiviral medications for hepatitis C were approved in 2013, even after factoring in the cost of treatment, Medicaid has saved an estimated $15 billion in avoided health care costs and nearly 285,000 Medicaid enrollees are estimated to have been cured. (Source: The Catalyst)
Source: The Catalyst - January 5, 2023 Category: Pharmaceuticals Authors: Lindsey Seidlitz Tags: Drug Cost Hepatitis C Medicaid Source Type: news